EA202192133A1 - Моногидрат гидрохлорида рогаратиниба и его твердые состояния - Google Patents

Моногидрат гидрохлорида рогаратиниба и его твердые состояния

Info

Publication number
EA202192133A1
EA202192133A1 EA202192133A EA202192133A EA202192133A1 EA 202192133 A1 EA202192133 A1 EA 202192133A1 EA 202192133 A EA202192133 A EA 202192133A EA 202192133 A EA202192133 A EA 202192133A EA 202192133 A1 EA202192133 A1 EA 202192133A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rogaratinib
hydrochloride monohydrate
solid states
methyl
monohydrate
Prior art date
Application number
EA202192133A
Other languages
English (en)
Inventor
Йорг Грис
Йоханнес ПЛАТЦЕК
Клаус-Кристиан Хезельхофф
Кай Ловис
Original Assignee
Байер Акциенгезельшафт
Байер Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Акциенгезельшафт, Байер Фарма Акциенгезельшафт filed Critical Байер Акциенгезельшафт
Publication of EA202192133A1 publication Critical patent/EA202192133A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Кристаллическая форма [4-{[4-амино-6-(метоксиметил)-5-(7-метокси-5-метил-1-бензотиофен-2-ил)пирроло[2,1-f][1,2,4]триазин-7-ил]метил}пиперазин-2-он-гидрохлорида] формулы (III)которая представляет собой моногидрат, способ ее получения, содержащие ее фармацевтические композиции и ее применения для контроля нарушений.
EA202192133A 2019-01-31 2020-01-27 Моногидрат гидрохлорида рогаратиниба и его твердые состояния EA202192133A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19154781 2019-01-31
PCT/EP2020/051884 WO2020156982A1 (en) 2019-01-31 2020-01-27 The monohydrate of rogaratinib hydrochloride and solid states thereof

Publications (1)

Publication Number Publication Date
EA202192133A1 true EA202192133A1 (ru) 2022-02-09

Family

ID=65276007

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192133A EA202192133A1 (ru) 2019-01-31 2020-01-27 Моногидрат гидрохлорида рогаратиниба и его твердые состояния

Country Status (21)

Country Link
US (1) US20220098201A1 (ru)
EP (1) EP3917929A1 (ru)
JP (1) JP2022519081A (ru)
KR (1) KR20210119994A (ru)
CN (1) CN113382997A (ru)
AU (1) AU2020214188A1 (ru)
BR (1) BR112021012876A2 (ru)
CA (1) CA3128073A1 (ru)
CL (1) CL2021001977A1 (ru)
CO (1) CO2021009660A2 (ru)
DO (1) DOP2021000162A (ru)
EA (1) EA202192133A1 (ru)
EC (1) ECSP21056314A (ru)
GE (1) GEP20237531B (ru)
IL (1) IL284927A (ru)
JO (1) JOP20210204A1 (ru)
MA (1) MA54856A (ru)
MX (1) MX2021009173A (ru)
SG (1) SG11202107919YA (ru)
TW (1) TW202035413A (ru)
WO (1) WO2020156982A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011635A (es) * 2015-03-09 2018-02-09 Bayer Pharma AG Combinaciones que contienen 2,3-dihidroimidazo[1,2-c]quinazolina sustituida.
CN113720956B (zh) * 2021-09-08 2022-03-29 广州国标检验检测有限公司 一种气质联用检测药物中硫酸酯的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2436877T3 (es) * 2005-11-17 2014-01-07 OSI Pharmaceuticals, LLC Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP5512975B2 (ja) * 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
UY34484A (es) 2011-12-15 2013-07-31 Bayer Ip Gmbh Benzotienilo-pirrolotriazinas disustituidas y sus usos

Also Published As

Publication number Publication date
CL2021001977A1 (es) 2022-02-25
JOP20210204A1 (ar) 2023-01-30
DOP2021000162A (es) 2021-09-15
CO2021009660A2 (es) 2021-08-09
BR112021012876A2 (pt) 2021-09-08
EP3917929A1 (en) 2021-12-08
MX2021009173A (es) 2021-09-10
GEP20237531B (en) 2023-08-25
JP2022519081A (ja) 2022-03-18
TW202035413A (zh) 2020-10-01
MA54856A (fr) 2022-05-04
CA3128073A1 (en) 2020-08-06
SG11202107919YA (en) 2021-08-30
WO2020156982A1 (en) 2020-08-06
ECSP21056314A (es) 2021-08-31
CN113382997A (zh) 2021-09-10
AU2020214188A1 (en) 2021-07-15
KR20210119994A (ko) 2021-10-06
US20220098201A1 (en) 2022-03-31
IL284927A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
PH12020500125A1 (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
WO2020140005A8 (en) 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
PH12021550045A1 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021015605A (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
SA518391518B1 (ar) مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية
PH12020551639A1 (en) Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase
EA202192019A1 (ru) Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
SI3106463T1 (en) Compounds of substituted pyrazolo (1,5-) pyrimidine as inhibitors of TRK kinase
EA202091475A1 (ru) ПРОИЗВОДНЫЕ 5-(2-(2,5-ДИФТОРФЕНИЛ)ПИРРОЛИДИН-1-ИЛ)-3-(1H-ПИРАЗОЛ-1-ИЛ)ПИРАЗОЛО[1,5-а]ПИРИМИДИНА И РОДСТВЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Trk КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
EA200400289A1 (ru) Производные аминоизоксазола, активные в качестве ингибиторов киназы
EA202192029A1 (ru) Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
PH12021551117A1 (en) 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer
EA202192133A1 (ru) Моногидрат гидрохлорида рогаратиниба и его твердые состояния
EA202191801A1 (ru) Гетероциклические ингибиторы mat2a и способы применения для лечения рака
EA202091016A1 (ru) Пиримидиновое соединение в качестве ингибитора jak киназы
MX2020010563A (es) Derivados de pirazolo-triazina y/o pirazolo-pirimidina farmaceuticamente activos.
SA519401322B1 (ar) مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2
WO2014106800A3 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
BR112012020557A2 (pt) formas cristalinas de sódio 4- {[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido [5,4-d] [2] benzazepin-2-il]-amino}-2 metoxibenzoato de sódio.
MX2020013896A (es) Proceso de fabricacion e intermediarios para un compuesto de pirrolo[2,3-d]pirimidina y su uso.
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
MX2010005787A (es) Derivados de imizado-tiazole en la forma de inhibidores de cinasa de proteina.
MX2022005951A (es) Compuestos de pirrolotriazina que actuan como inhibidor de mnk.
MX2022004427A (es) Metodos para el tratamiento de la trombocitopenia inmunitaria mediante la administracion de (r)-2-[3-[4-amino-3-(2-fluoro-4-feno xi-fenil)pirazolo[3,4-d]pirimidin-1-il]piperidino-1-carbonil]-4-m etil-4-[4-(oxetan-3-il)piperazin-1-il]pent-2-enonitrilo.
BR112018075823A2 (pt) sais farmacêuticos de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida e suas formas cristalinas